- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02180022
Effects of Onion Peel Extract on Endothelial Function
July 1, 2014 updated by: Weon Kim, Kyunghee University Medical Center
Effect of Onion Peel Extract on Endothelial Function and Endothelial Progenitor Cells in Overweight and Obese Subjects
Acute or chronic intake of polyphenol-rich foods has been reported to improve endothelial function.
Quercetin, found abundantly in onion, is a potent antioxidant flavonoid.
This study was designed to investigate whether consumption of onion peel extract (OPE) improves endothelial function in healthy overweight and obese subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Epidemiological studies have shown a rapid increase in the prevalence of overweight and obesity, not only in adults but also in children and adolescents, thus increasing the risk of early development of cardiovascular disease (CVD).
Quercetin, found abundantly in onion, prevents the induction of endothelial dysfunction, superoxide production, and overexpression by angiotensin II in the rat aorta.
Furthermore, in our previous study we showed that supplementation with quercetin-rich onion peel extract (OPE) influenced adipokine expression, thus addressing its modulatory effect on obesity-induced inflammation, and improved insulin resistance by alleviating the metabolic dysregulation of free fatty acids, suppressing oxidative stress, upregulating glucose uptake, and downregulating inflammatory gene expression.
But there are limited studies on the relationship between quercetin supplementation and endothelial dysfunction in humans.
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 130-702
- Kyung Hee University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 20 to 60 years
- BMI >23 kg/m2
- abdominal circumference > 90 cm in males or >85 cm in females
Exclusion Criteria:
- hypertension (>140/90 mmHg),
- diabetes
- any cardiovascular disease,
- kidney disease,
- thyroid disease
- cerebrovascular disease
- liver disease (bilirubin level >2 mg/dl)
- pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Patients treated with placebo for 12 weeks
|
After randomization, placebo was treated for 12 weeks
|
|
Experimental: Onion peel extract
Patients treated with onion peel extract for 14 days
|
After randomization, onion peel extract was treated for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The difference of endothelial function
Time Frame: 12 weeks after study drug treatment
|
The difference of forearm FMD (flow meidated dilation) achieved following study drug treatment
|
12 weeks after study drug treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The difference of EPC (endothelial progenitor cell) counts
Time Frame: 12 weeks after study drugs treatment
|
After appropriate gating based on low cytoplasmic granularity and low expression of CD45, CD34+VEGFR2+ cells were counted and expressed as the number of cells/106 total events or number of cells/100 µL of blood.
|
12 weeks after study drugs treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The composite measure of change of blood pressure, heart rate, body weight and blood chemistry
Time Frame: up to 12 weeks
|
up to 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Weon kim, MD, PhD, Kyung Hee University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
June 28, 2014
First Submitted That Met QC Criteria
July 1, 2014
First Posted (Estimate)
July 2, 2014
Study Record Updates
Last Update Posted (Estimate)
July 2, 2014
Last Update Submitted That Met QC Criteria
July 1, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Onion-EPC
- Seoul, Korea (Other Grant/Funding Number: No. 1111473)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.